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1 
Abstract 28 
Objectives: The effectiveness of vaccines is known to be altered by a range of psychological 29 
factors. We conducted a systematic review to evaluate the effects of psychological 30 
interventions on the ability of vaccines to protect against disease, as measured by antibody 31 
responses.  32 
Methods: Electronic databases (EMBASE, Medline, PsychINFO, CINAHL) were searched from 33 
their inception to 6th February 2018. 34 
Results: The search yielded 9 eligible trials conducted with 1603 participants and four broad 35 
categories of intervention: meditation/mindfulness (n=3), massage (n=3), expressive writing 36 
(n=2) and cognitive behavioural stress management (n=1). Some evidence of benefit on the 37 
antibody response to vaccination was observed in 6/9 of all trials and in 4/7 of randomised 38 
controlled trials. However, effects on antibody levels were often mixed, with only 3 of 6 39 
trials showing benefit demonstrating an improvement in all antibody outcomes and at all 40 
time points assessed. Trials demonstrating benefit also provided direct or indirect evidence 41 
of adequate adherence with the intervention; and in 50% of these trials, there was also 42 
evidence that the intervention was effective in changing the mediating psychological 43 
constructs targeted by the intervention. 44 
Conclusions: This literature is characterised by considerable heterogeneity in terms of 45 
intervention type, vaccine type, age of participants and the temporal relationship between 46 
vaccination and intervention. We conclude that there is early evidence to suggest that 47 
psychological interventions may enhance the antibody response to vaccination. However, 48 
the effects are inconsistent, with the greatest likelihood of benefit seen in trials evidencing 49 
adequate adherence with the intervention. Future work would benefit from rigorous 50 
2 
intervention development that focuses on achieving adequate adherence and large well-51 
controlled randomised trials with a focus on an agreed set of outcomes. 52 
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Introduction  57 
The Centres for Disease Control stated that vaccination is among the ten most 58 
significant health achievements ever documented[1]; and for many conditions they have 59 
been an enormous success (e.g., smallpox). However, vaccinations are not universally 60 
effective, with multiple factors related to the vaccine and the vaccine recipient known to 61 
influence efficacy [2, 3]. With regard to the latter, there are several populations in whom 62 
the evidence for vaccine effectiveness is equivocal. These include populations with 63 
underlying immune impairment due to advancing age [3, 4] and/or the presence of co-64 
existing diseases (e.g., cancer) [5]. As a consequence, vaccines may be most likely to fail in 65 
those they most seek to benefit [6, 7]. 66 
This has prompted research into strategies to enhance the immune response to 67 
vaccination, so called vaccine adjuvants. The aim of such interventions is to optimise the 68 
response of the immune system to the vaccine antigens and, in so doing, increase the 69 
likelihood that the vaccine confers protection. Within this context, there has been a growing 70 
interest in the potential for non-pharmacological factors to act as vaccine adjuvants. This is 71 
borne out of a literature which has demonstrated that psychological and behavioural factors 72 
such as mood, diet and physical activity can modulate aspects of functional and 73 
enumerative immunity [8], including responses to vaccination [9, 10]. For example, a meta-74 
analysis of 13 studies examining the relationship between psychological stress and antibody 75 
responses following influenza vaccination reported evidence of a significant negative 76 
relationship, such that greater levels of stress (regardless of how it was measured) were 77 
associated with lower levels of antibody [9]. Similarly, a review of cross-sectional, 78 
observational and randomised controlled studies investigating the relationship between 79 
chronic and acute exercise and immune responses to vaccination concluded that the 80 
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immune response appears to be augmented by exercise [11]. Comparable evidence also 81 
exists for a range of dietary factors. For example, both vitamin D and zinc have been shown 82 
to modulate the functioning of the immune system [12, 13] . 83 
This systematic review aims to provide a comprehensive evaluation of the effects of 84 
psychological interventions on the human antibody response to vaccination; with a view to 85 
informing the debate as to whether they could be used to optimise vaccine efficacy. We 86 
sought to be inclusive in this review. Thus, the term psychological was used to capture any 87 
treatment that could be broadly considered to be aiming to improve the vaccine response 88 
by targeting a psychological construct or process known to effect immunity (e.g., mood, 89 
relaxation, pain, etc.), but we did not require the intervention to draw on psychological 90 
theory. This was necessary to ensure a comprehensive assessment of the relevant literature, 91 
given that this is a field known to be characterised by a relative absence of theory driven 92 
enquiry [14]. We examined the evidence from all eligible trials conducted with human 93 
participants that measured the effects of a psychological intervention on the antibody 94 
response to standard dose vaccinations.  95 
Furthermore, although a range of immunological outcomes have been reported in 96 
the literature, we chose to focus this review on the antibody response only. Vaccines 97 
contain live, attenuated, modified, or killed microorganisms (or their toxins) and, when 98 
administered, they stimulate an immune response, the nature of which depends on the type 99 
of microorganism administered. However, most often the cascade of immune activity 100 
following vaccination ends with the production of antibodies. Thus, antibody responses can 101 
be accepted as a surrogate and universal marker of an effective immune response to 102 
vaccination.  103 
5 
It is worth noting that there are two classes of vaccine that stimulate B cells to 104 
produce antibodies: thymus-dependent (i.e. T cell-dependent) or thymus-independent (i.e. 105 
T cell-independent) vaccines. Psychological factors have been shown to influence the 106 
response to both in comparable ways [15]. Thus, we had no apriori reason to expect that 107 
the effect of the non-pharmacological interventions considered in this review would affect 108 
these two classes of vaccines differently. 109 
 110 
Systematic Review Methods 111 
Search strategy and selection criteria 112 
We searched electronic databases (EMBASE, Medline, PsychINFO, and CINAHL) from 113 
their inception to 6th February 2018 (see Appendix 1 for details of the search strategy). Our 114 
search was constructed to identify all non-pharmacological interventions and identified 115 
three broad types of intervention: psychological, physical activity/exercise and 116 
dietary/nutritional interventions. However, given the diversity in types of intervention 117 
within and between each category, the results from the physical activity/exercise and 118 
dietary/nutritional interventions are to be the subject of separate manuscripts. Hereafter, 119 
we uƐĞ ?Ŭ ?ƚŽĚĞŶŽƚĞŶƵŵďĞƌŽĨĂƌƚŝĐůĞƐĂŶĚ ?Ŷ ?ƚŽĚĞŶŽƚĞ ƵŵďĞƌŽĨƉĂƌƚŝĐŝƉĂŶƚƐŝŶƚŚŝƐ120 
manuscript: 121 
No language restrictions were applied. Only primary studies published in peer-122 
reviewed journals were considered for inclusion. Review articles were excluded, but their 123 
reference lists were examined for relevant papers. We also hand-searched reference lists of 124 
included papers and contacted subject experts for additional relevant papers. The following 125 
study inclusion criteria were applied: (1) human adult, child and infants receiving any type of 126 
vaccine; (2) studies explicitly concerned with evaluating the therapeutic (i.e., beneficial) 127 
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effects of an intervention on the immune response to the vaccine; (3) the intervention 128 
targeted a psychological construct known to effect immunity (e.g., mood, relaxation, etc.) 129 
but was not required to explicitly draw on psychological theory; (4) studies in which 130 
participants received standard doses of vaccine; (5) comparative studies (randomised and 131 
non-randomised); (6) studies providing a quantitative assessment of the antibody response 132 
to the vaccination and (7) examined the association between the intervention and the 133 
antibody response. To be included, studies had to meet all 7 criteria. 134 
Antibody responses are typically quantified in absolute levels, as captured by titres, 135 
or binary outcomes that capture a change in antibody levels: with the outcomes 136 
 ?ƐĞƌŽƌĞƐƉŽŶĚĞƌ ?ƌĞƐƉŽŶĚĞƌ ?ĂŶĚ ?ƐĞƌŽĐŽŶǀĞƌƐŝŽŶ ?ƵƐĞĚŵŽƐƚĐŽŵŵŽŶůǇ ?dǇƉŝĐĂůůǇ ?137 
seroresponding following vaccination is defined as a rise in serum antibody of a particular 138 
magnitude (e.g., a four-fold increase or greater). Seroconversion refers to the presence of 139 
antibody specific to the vaccine antigens in the blood. All approaches to quantifying the 140 
antibody response were included in this review.  141 
It is usual in reviews of this kind to specify the primary outcome in advance. In the 142 
case of the present body of work this might have included a focus on a specific type of 143 
antibody measure (e.g., absolute antibody levels) and a specific time-point following 144 
vaccination (e.g., 4 weeks post-vaccination). However, this was not possible in this review 145 
because common practice in this field has been to report multiple antibody outcomes; 146 
measure these on more than one occasion post-vaccination and not always specify the 147 
primary or secondary outcomes. The absence of a consistent approach to measuring the 148 
effects of psychological interventions on the antibody response to vaccination led us to 149 
ŽƉĞƌĂƚŝŽŶĂůŝƐĞ ?ĂŶ ŝŵƉƌŽǀĞŵĞŶƚŝŶƚŚĞĂŶƚŝďŽĚǇƌĞƐƉŽŶƐĞ ?ĂƐĂƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ150 
 ?ƉA? ? ? ? ? ?ĞŶŚĂŶĐĞŵĞŶƚŝŶŽŶĞŽƌŵŽƌĞĂŶƚŝďŽĚǇŽƵƚĐŽŵĞ ?ĂƚĂŶǇƚŝŵĞƉŽŝŶƚƉŽƐƚ-151 
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vaccination, i.e., evidence of improvement across all outcomes and all times post-vaccine 152 
was not required. Although this approach is symptomatic of the extant literature, it does 153 
increase the risk of bias. Thus, in our summary table we describe all antibody outcomes 154 
reported in each trial, and in the manuscript comment on the proportion of outcomes, 155 
relative to the total outcomes measured, exhibiting an improved antibody response.  156 
The titles and abstracts of the papers were initially assessed against the inclusion 157 
criteria by two independent reviewers who removed those that did not meet the criteria. 158 
Full text papers were retrieved and read in full by both reviewers. Disagreements at each 159 
stage of the selection process were resolved through discussion between the reviewers. For 160 
example, at title and abstract review it was not always clear if a vaccine had been 161 
administered or antibodies measured. This was resolved by review of the full-text. The 162 
search procedure can be seen in Figure 1.  163 
 164 
INSERT FIGURE 1 ABOUT HERE 165 
 166 
Data extraction and assessment of risk of bias 167 
Data were extracted by two reviewers directly from the papers into tables. These 168 
data included the sample size, characteristics of the participants, a description of the 169 
intervention, type of vaccine administered, the primary outcome, number of follow-ups and 170 
a summary of the major findings.  171 
Risk of bias for individual studies was assessed independently by two reviewers using 172 
ƚŚĞŽĐŚƌĂŶĞŽůůĂďŽƌĂƚŝŽŶ ?ƐƌŝƐŬŽĨďŝĂƐƚŽŽů[16]. The tool refers to seven items that assess: 173 
method of randomisation, allocation concealment, blinding of participants, study personnel, 174 
outcome assessments, how missing data were handled and evidence of selective reporting. 175 
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All discrepancies between reviewers were resolved through discussion. For example, there 176 
was some discrepancy regarding what could be considered selective reporting. Discussions 177 
led to reviewers agreeing that this could only be determined if a published protocol was 178 
available containing the relevant details. All agreed ratings are reported in Table 1. 179 
 180 
INSERT TABLE 1 ABOUT HERE 181 
Effect Sizes 182 
 ĞƚǁĞĞŶŐƌŽƵƉĞĨĨĞĐƚƐŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ǁĞƌĞĐĂůĐƵůĂƚĞĚĨŽƌĂůůĂŶƚŝďŽĚǇŽƵƚĐŽŵĞƐ183 
using Comprehensive Meta-Analysis (Version 3): Englewood, NJ; Biostat: https://www.meta-184 
analysis.com/). These were calculated using post-vaccination means, standard deviations 185 
and sample size for continuous outcomes and number of events per group used for 186 
dichotomous outcomes. In two cases [17, 18], where these statistics were not reported in 187 
the published manuscript, effect sizes were calculated on the basis of reported inferential 188 
tests assessing between group differences in changes from pre-vaccination antibody levels. 189 
In the case of the Davidson et al. trial [17] this was because no other data were available. In 190 
the case of the Vedhara et al trial [18], the measure presented was seroconversion and thus 191 
ǁĂƐ ?ŝŶĞĨĨĞĐƚ ? ?ĐŚĂŶŐĞĨƌŽŵďĂƐĞůŝŶĞ ? ? 192 
For five studies, insufficient statistics of any kind were published to calculate effect 193 
sizes. Authors of all 5 studies were contacted and two provided additional data, thus 194 
allowing us to calculate effect sizes for 6/9 articles in total (see Table 2). 195 
ĨĨĞĐƚƐŝǌĞƐǁĞƌĞŝŶƚĞƌƉƌĞƚĞĚŝŶůŝŶĞǁŝƚŚŐƵŝĚĞůŝŶĞƐĨŽƌŽŚĞŶ ?ƐĚ ?ƐŵĂůůA? ? ? ?196 
medium= .5, large= .8 [19], with positive values interpreted as the intervention having 197 
enhanced antibody responses compared to controls. However, due to the heterogeneous 198 
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nature of the trials identified (in terms of vaccinations used, intervention type, and method 199 
of antibody measurement) we did not meta-analyse these data. 200 
 201 
Results 202 
Summary of findings 203 
The search yielded nine eligible papers reporting nine trials which covered four 204 
broad categories of intervention: meditation/mindfulness (k=3), massage (k=3), expressive 205 
writing (k=2) and cognitive behavioural stress management (k=1). We elected to include the 206 
massage trials in this review of psychological interventions for two main reasons. First, they 207 
ŵĞƚŽƵƌĐƌŝƚĞƌŝĂŽĨ ?ŝŶƚĞƌǀĞŶƚŝŽŶƐƚĂƌŐĞƚŝŶŐĂƉƐǇĐŚŽůŽŐŝĐĂůĐŽŶƐƚƌƵĐƚŬŶŽǁŶƚŽĞĨĨĞĐƚ208 
immunity ?ŝŶƚŚĂƚƚŚĞŵĂƐƐĂŐĞŝŶƚŚĞƐĞƚƌŝĂůƐǁĂƐĚĞƐŝŐŶĞĚƚŽƌĞĚƵĐĞƉĂŝŶŽƌĞŶŚĂŶĐĞŵŽŽĚ ?209 
Second, we considered these interventions to be wholly different from the exercise/physical 210 
activity based interventions identified in our searches, all of which were concerned with 211 
participants actively engaging in some form of physical activity. This contrasts with massage 212 
where subjects are the passive recipients of some degree of physical manipulation. 213 
Seven randomised controlled trials were identified, one study used matched 214 
controls, and another used waiting-list controls. All studies provided data on at least one 215 
measure of adherence or effects on a mediating mechanism. The total sample size across all 216 
studies was 1603 (range: 40-413). The average age of participants ranged from 2 months to 217 
80 years. Two trials were conducted with infants (2-6 months), five with adults (21-60 218 
years), and two in older adults (75-80 years). Five trials focussed on responses to seasonal 219 
influenza vaccination, two to hepatitis B vaccinations, and two to 220 
diphtheria/tetanus/pertussis (DTP) vaccination. Four trials targeted groups who could be 221 
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considered to be at potential risk of vaccine failure: two with young infants [20, 21] and two 222 
with older adults [18, 22]. The length of the interventions ranged from single sessions of 1 223 
minute [20] to 3 x 1 hour sessions per week for 20 weeks [22]. Five trials administered their 224 
vaccination post-intervention; two before or at the first intervention session and two during 225 
the intervention. 226 
Two-thirds of all trials (k=6/9), and over half of all RCTs (k=4/7), reported some 227 
evidence of a statistically significant improvement in the antibody response to vaccination 228 
[17, 18, 20, 22-24]; two showed no benefit [21, 25] and one showed evidence of an 229 
impaired antibody response in the intervention group [26]. Intervention effect sizes ranged 230 
from g=-0.73 to g=1.13 (see Table 2). Trials showing evidence of an improved immune 231 
response to vaccination, and in which effect sizes could be calculated, typically exhibited 232 
moderate to large effects [17, 18, 24]. 233 
When examining the six trials that showed some evidence of benefit in more detail, 234 
it was clear that there was variability in both the number of outcomes reported (ranging 235 
from 1-25) and the proportion of these that exhibited evidence of a statistically significant 236 
improvement in the antibody response. For 50% of these trials (k=3) all antibody outcomes 237 
reported improved significantly in the intervention group compared with the control group 238 
[17, 18, 24]. In contrast, the study by Hsu [20], considered 5 outcomes over 5 time points, 239 
only 12 of which (48%) attained significance in the expected direction. Two outcomes 240 
showed significantly greater antibody levels in the control arm (both at 2 months post-241 
vaccine) and the direction of the non-significant comparisons indicated higher antibody 242 
levels in the control arm for 7/11 outcomes. 243 
The study by Yang [22], reported 6 between-group comparisons, 2 of which (33%) 244 
attained statistical significance in the expected direction. The direction of all the non-245 
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significant between group comparisons in this study were in the expected direction (i.e., 246 
greater antibody levels or protective titres observed in the intervention arm). Finally, the 247 
post-hoc analysis by Stetler [23] which showed evidence of improved antibody responses, 248 
did so for only 1 out of 3 viral strains (33%). The results for the other viral strains were not 249 
presented in the manuscript and so we could not determine the direction of these non-250 
significant comparisons. 251 
There appeared to be no systematic differences in intervention effects based on the 252 
nature of the vaccine (influenza, hepatitis B and DTP vaccines used in trials showing 253 
benefit/impairment and not); or the timing of the vaccination relative to the intervention 254 
(i.e., whether vaccination occurred pre, during or post-intervention). Trials showing no 255 
benefit/impairment also did not appear to differ markedly in their duration, from those that 256 
did show benefit (median total number of intervention days: 4 versus 6 respectively). 257 
However, they did appear to differ in intensity (i.e., median number of minutes engaged in 258 
formal intervention sessions): with median intensity (not including unsupervised 259 
intervention practice) over the intervention period of 180 minutes for trials showing no 260 
benefit/impairment versus 280 minutes for trials reporting benefit. They also differed in 261 
sample size: with trials showing no benefit/ impairment typically being larger than the trials 262 
showing some evidence of benefit (medians n=149 and n=49 respectively). Although this 263 
latter observation may be attributable, in part, to a single very large trial of 413 participants 264 
[21]. 265 
In considering this literature in more detail, we next give consideration to findings 266 
according to intervention type and methodology 267 
Intervention Type and Methodology 268 
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No single intervention approach was examined in more than three trials. Thus it is 269 
not yet possible to consider the relative benefits of each intervention approach in the 270 
context of such a modest evidence base. However, some early patterns emerge if we 271 
consider aspects of intervention methodology, relating in particular to (a) adherence with 272 
the interventions (indicated by the number of intervention sessions attended); (b) 273 
intervention effects on purported mediating mechanisms i.e., whether it had a beneficial 274 
effect on constructs targeted by the intervention (e.g., improved mood) and (c) 275 
characteristics of participants at baseline (i.e., could they be considered to be at risk of 276 
vaccination failure). 277 
Intervention adherence: Only three trials formally reported on intervention 278 
adherence [18, 22, 26], but it is possible to infer levels of adherence from other details (e.g., 279 
degrees of freedom) presented in a further three trials [20, 23, 24]. All six of these trials 280 
evidenced adequate to good adherence, as measured by participants attending >75% of 281 
intervention sessions, and all but one [26] reported evidence of an enhanced antibody 282 
response to vaccination in the intervention group compared with the control group. In 283 
contrast, of the three trials that did not provide data on adherence [17, 21, 25], only one 284 
reported evidence of an improved vaccination response. 285 
Mediating mechanisms: Nearly all trials (k=8/9) reported evidence relating to one or 286 
more hypothesised mediating mechanism: mood [17, 18, 23, 24, 26]; brain activity [17]; 287 
cognitive change [23-25]; pain and other vaccine related adverse events [20, 21]. Of these, 288 
three trials were characterised by the intervention having no effect or an adverse effect on 289 
their hypothesised mechanisms [21, 25, 26]; and all three showed no evidence of a 290 
beneficial effect on vaccine effectiveness. In contrast, three out of the five trials reporting 291 
evidence of a beneficial effect on vaccine effectiveness showed that the purported 292 
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mechanisms had also been changed in the expected direction [17, 23, 24]. The remaining 293 
two trials showing benefit observed no effect of their intervention on their hypothesised 294 
mechanism (mood: [18]) or an adverse effect (pain and fever: [20]). 295 
Participant characteristics: Four out of nine trials were conducted with individuals at 296 
risk of vaccine failure due to their age [18, 20-22]. All but one of these trials [21] reported a 297 
beneficial effect of their intervention on the antibody response to vaccination. However, 298 
evidence of an enhanced immune response to vaccination following interventions 299 
conducted in healthy adults was also not uncommon, with three out of five of these trials 300 
reporting benefit [23-25]. 301 
 302 
Discussion 303 
This review identified nine trials in which the effects of psychological interventions 304 
on the antibody response to vaccination were examined. This literature was modest in size 305 
and characterised by considerable heterogeneity in terms of the type of intervention, age of 306 
participants, vaccine type, intervention duration and intensity and approaches to assessing 307 
the antibody response to vaccination. When examining the evidence according to the less 308 
ƐƚƌŝŶŐĞŶƚĐƌŝƚĞƌŝŽŶŽĨ ?ĂƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ ?ƉA? ? ? ? ? ?Ğnhancement in one or more 309 
antibody outcome at any time point post-ǀĂĐĐŝŶĂƚŝŽŶ ? ?ǁĞŽďƐĞƌǀĞĚƚŚĂƚƚǁŽ-thirds of trials 310 
reported some evidence of benefit in the antibody response to vaccination, and in those 311 
where an effect size could be calculated, the results suggested evidence of a moderate to 312 
large effect. However, a closer examination of these trials suggests that caution should be 313 
exercised when interpreting these findings. For example, only 50% of trials reported a 314 
significant improvement across all antibody outcomes and at all time points; while for the 315 
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remaining trials, evidence of improvement was seen only for between 33-48% of outcomes 316 
and time-points considered.  317 
The weight of the evidence offers early support for the view that psychological 318 
interventions may help to prevent disease through their ability to improve the antibody 319 
response to vaccinations and thus make vaccines more effective. Furthermore, the data 320 
suggest the effect could be generalizable across a range of vaccinations and at all stages of 321 
the immune response: evidenced by the fact that intervention effects were unrelated to 322 
vaccine type or the timing of the intervention relative to the vaccine. However, this 323 
conclusion should be tempered by several caveats. 324 
First, while our outcome measure (i.e., antibody responses) is widely used as a 325 
surrogate for protection from disease [27], vaccine effectiveness is more accurately 326 
determined in studies that report laboratory confirmed disease [28]. Such trials, do 327 
however, require longer follow-ups, are likely to be more costly and thus are rarely 328 
undertaken in the context of psychological interventions.  329 
Second we wish to acknowledge that the way we determined if there was evidence 330 
of an enhanced immune response to vaccination, and thus improved protection from 331 
disease, lacked precision and could have increased the risk of bias. We considered an 332 
improvement in at least one immune outcome (not necessarily all immune outcomes), at 333 
any time point, as evidence of an enhanced response to vaccination i.e., improvement 334 
across all outcome measures and at specific times was not required. This was necessary 335 
because of variability in the literature in the ways that the antibody response has been 336 
measured; at what time points; and the failure in many trials to specify primary or 337 
secondary outcomes. The former poses a particular problem for this field because it is well 338 
known that findings from different immunological methods and outcomes do not correlate 339 
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well [29, 30]. Thus, it is perhaps not reasonable, for example, to expect improvements in 340 
absolute antibody levels to translate into improved rates of seroprotection. Similarly, the 341 
optimal timing of antibody outcomes is influenced by whether the focus is on a primary or 342 
secondary immune response (a primary response is slower than a secondary response) [31-343 
34]; and whether the focus is on the peak antibody response or long-term persistence in 344 
immunity (again the former would be measured earlier than the latter). In addition, the 345 
choice of primary outcome may also be influenced by the nature of the vaccine itself [35]. 346 
These considerations have contributed to capriciousness in outcome assessment in this 347 
literature which, in turn, serves only to impede attempts to synthesise the evidence. We 348 
suggest that future research in this area would benefit from the development of an agreed 349 
set of outcomes as is advocated by the COMET initiative [36]. COMET seeks to achieve 350 
agreement on the minimum outcomes that should be measured and reported in clinical 351 
trials with a view to facilitating comparisons between trials and evidence synthesis. The 352 
initiative is typically focussed on single disease entities. However, the principles of COMET 353 
are of relevance to this field. In addition, we would recommend greater uptake of pre-354 
registration of trial designs and analysis plans as this would alleviate concerns regarding 355 
 ?ƌĞƐĞĂƌĐŚĞƌĚĞŐƌĞĞƐŽĨĨƌĞĞĚŽŵ ?[37] which can also lead to false-positive results. 356 
The third caveat relates to the potential for the significance of these findings to be 357 
influenced by the  ?file drawer effect ? or publication bias. This phenomenon, now widely 358 
recognised in the psychological and medical sciences, refers to the likelihood of positive 359 
findings being more likely to appear in the published literature than null findings. Some 360 
estimates of the size of the file drawer problem suggest that there may be 3 times more 361 
negative trials than those found in the published literature. For example, in a now classic 362 
study, Smart [38] examined publications in psychological journals and reported that while 363 
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studies with negative findings typically accounted for 9% of published papers, negative 364 
findings were reported in 20.5% of abstracts of papers presented at a mainstream 365 
psychological conference in a single year and 30.2% of dissertation abstracts from the same 366 
year. These findings support the view that research is much more likely to be published if 367 
the results are positive. 368 
A host of factors are known to drive the file drawer effect [39], but the implications 369 
for reviews like the present one are clear: it can lead to an over-estimation of the size of the 370 
treatment effect. Like many authors, we sought to mitigate this risk by contacting known 371 
authors in the field to enquire about data from unpublished trials (none were reported). We 372 
also sought to be as inclusive as possible in our identification of the literature by not 373 
restricting ourselves to studies in which the intervention explicitly drew on psychological 374 
theory. Indeed, we are somewhat reassured that this review reflects the extant literature by 375 
the fact that three of the nine included studies reported null findings or evidence in support 376 
of a psychological intervention impairing the antibody response. Furthermore, while we 377 
were unable to locate and include any unpublished studies, there is a contrasting view that 378 
this could be a strength of the present work because unpublished research is not without 379 
bias (e.g., due to potentially being of lower quality, not having been subjected to peer 380 
review etc.). Indeed, a recent simulation study concluded that selective publication (as 381 
opposed to publishing everything) results in a more accurate estimate of effect sizes [40].  382 
The debate on the file drawer effect is likely to continue for some time to come. But 383 
in the context of this nascent field, typically characterised by modest sample sizes, we 384 
strongly encourage authors to always seek to publish their findings regardless of observed 385 
effects so that the scientific community can arrive at an informed view on whether 386 
psychological interventions represent a viable means for enhancing vaccine effectiveness. 387 
17 
Further observations arising from this review worthy of comment include, first, that 388 
we cannot yet determine what type of intervention (e.g., mindfulness versus CBT) might be 389 
most effective in enhancing vaccinations and reducing disease risk because no single 390 
intervention has been examined in more than 3 studies. Second, that observations 391 
regarding intervention methodology pointed towards effective interventions being more 392 
likely to involve treatments that were more intensive (reflected by the median time spent in 393 
receipt of formal intervention sessions), although not necessarily of a longer duration, and 394 
where the intervention was effective in modifying the psychological constructs being 395 
targeted. We also observed some potentially interesting findings in relation to intervention 396 
adherence and effects on the antibody response. For six of the nine trials, adherence data 397 
were reported (or could be inferred) and the majority of these (k=5/6) showed evidence of 398 
both adequate adherence and an improved antibody response to vaccination. For the 399 
remaining three trials it was not possible to determine if adequate adherence had been 400 
achieved, but two of these failed to show evidence of benefit on the antibody response. We 401 
cannot of course assume that the absence of adherence data is indicative of poor 402 
adherence. But the findings hint at this possibility and, at the very least, highlight the need 403 
for more rigorous reporting of trial methodology. 404 
Third, we did not observe any clear patterns in relation to the age of participants and 405 
the likelihood of psychological interventions enhancing the antibody response to 406 
vaccination: with some degree of improvement reported in trials with the very young, the 407 
elderly and healthy adults. 408 
Fourth, we suggest that the heterogeneity evident in this literature regarding 409 
intervention type and populations assessed may be a consequence of the absence of theory 410 
driven enquiry in this field. The theoretical context for much of this work comes from the 411 
18 
biopsychosocial model [41] which proposes that health and disease are a function of not 412 
only biology but the complex psychological and social influences that surround an individual. 413 
Although this framework has been influential, critics argue that its lack of specificity has 414 
meant that it does not make clear predictions or hypotheses that can be tested [14]. This 415 
lack of specificity is reflected in the literature reviewed here where both the populations 416 
under investigation (ranging from the very young to the very old) and the mechanisms 417 
targeted by the interventions were broad (ranging from mood, cognitive change and brain 418 
activity to pain). At this stage we have not achieved a clear understanding of which 419 
psychological factors may be the most influential in modifying immunity or how these 420 
relationships vary according to factors such as participant age and contextual factors such as 421 
the nature and type of stressor. Greater clarity on these issues would enable us to focus 422 
research effort on developing interventions that could optimise, rather than just improve, 423 
the effectiveness of vaccinations.  424 
An additional consequence of the varied literature examined here is that it 425 
necessarily precluded a meta-analysis and also impacted on the conclusions we could draw 426 
in this narrative synthesis. We also observed that studies where the intervention 427 
methodology was less robust (e.g., no data on intervention adherence) were less likely to 428 
find evidence of benefit. This makes it difficult to determine whether an absence of effect 429 
was due to the interventions per se, or the rigour with which they were implemented.  430 
Taken together, some clear directions for future research are evident. In particular, 431 
we would suggest that there is a need for more trials to examine the potential for 432 
psychological interventions to prevent disease by enhancing the effectiveness of vaccines; 433 
for these trials to be larger and conducted with a focus on an agreed set of outcomes; for 434 
authors to publish trial protocols in advance and be mindful of the consequences of 435 
19 
publication bias. It would also be advantageous for this work to adopt a clearer theoretical 436 
framework so that we can move towards a better understanding of which psychological 437 
influences on immunity are preeminent; and develop interventions that target these 438 
specifically whilst also maximising participant adherence. 439 
  440 
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Table 1: Risk of Bias Assessments 
Author Year 
R
a
n
d
o
m
 s
e
q
u
e
n
ce
 
g
e
n
e
ra
ti
o
n
 
A
ll
o
ca
ti
o
n
 
co
n
ce
a
lm
e
n
t 
B
li
n
d
in
g
 o
f 
p
a
rt
ic
ip
a
n
ts
 a
n
d
 
p
e
rs
o
n
n
e
l 
B
li
n
d
in
g
 o
f 
o
u
tc
o
m
e
 
a
ss
e
ss
m
e
n
t 
In
co
m
p
le
te
 o
u
tc
o
m
e
 
d
a
ta
 
S
e
le
ct
iv
e
 r
e
p
o
rt
in
g
 
O
th
e
r 
b
ia
s 
Davidson 2003 ? ? H ? ? ? L 
Hayney 2014 L L H L L ? L 
Hsu 1995 ? ? H ? ? ? L 
Huang 1999 ? ? H ? ? ? L 
Loft 2012 L ? H ? ? ? L 
Petrie 1995 ? ? H ? ? ? L 
Stetler 2006 ? ? H ? ? ? L 
Vedhara 2003 H H H ? L ? H 
Yang 2008 H H H ? L ? L 
L = low risk; ? = Unclear risk; H = High risk 
Table 2 Summary of Studies 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Davidson et al. 
(2003) 
 
USA 
 
Randomised 
controlled trial 
Intervention: n=25 
Control: n=16 
 
Healthy adults 
 
Mean age 36 years  
 
12 male, 29 female 
 
Intervention: mindfulness meditation 
program; sessions lasting 2.5  ? 3 hours, 
once a week, over 8 weeks; 7 hour silent 
retreat; unsupervised sessions 1 hour 6 
days a week for 8 weeks 
 
Control: wait-list control 
 
Adherence: not reported 
 
Mediating mechanisms: intervention 
group, compared with controls showed a 
reduction in negative affect and increased 
left sided brain activity. 
 
Vaccination administered after the 8 week 
intervention period 
Influenza 
 
Hemagglutination 
inhibition assay 
 
3-5 weeks & 8-9 weeks 
post-vaccination 
 
Change in HI antibody 
titres (composite of viral 
strains) 
 
Compared with control group, 
intervention participants displayed 
a significantly greater increase in HI 
antibody titres between 3-5 and 8-
9 weeks post-vaccine. 
 
 
 
g= 0.64 [.01, 1.27] 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Hayney et al. 
(2014) 
 
USA 
 
Randomised     
controlled trial  
Control group  
n= 51 
 
Exercise group  
n= 47 
 
MBSR/meditation 
group n= 51 
 
ĚƵůƚƐA? ? ?ǇĞĂƌƐ ?ŶŽ
previous/current 
experience of 
meditation; moderate 
ĞǆĞƌĐŝƐĞA? ?ƚŝŵĞƐĂ
week; any intense 
exercise 
 
Control group: mean 
age 59,  
10 male, 41 female 
 
MBSR group: mean 
age 60, 
9 male, 42 female 
 
Exercise group: mean 
age 59,  
8 male, 43 female 
Mindfulness-based stress reduction 
(MBSR) group: 8-week meditation 
intervention, weekly 2.5hr group sessions 
and 45mins home practice per day. 
 
Exercise group: 8 weeks in length, weekly 
2.5hr group sessions, 45mins daily home 
practice 
 
Waiting list control group: no intervention   
 
Adherence: not reported  
 
Mediating mechanisms: measures of 
mindfulness and exercise completed at 1 
and 8 weeks post-intervention indicate no 
between group differences in mindfulness 
and a difference in exercise between the 
exercise and control group at 1 and 8 
weeks post-intervention 
 
Timing: Vaccine given to all participants 
during week 6 of intervention 
Influenza 
 
Hemagglutination 
inhibition assay;  
 
 
 Baseline (pre-vaccine), 
 3 and 12 weeks post-
vaccine 
 
HI titres: Mean fold 
increase from baseline 
to 3 weeks (by viral 
strain); geometric mean 
titre (by viral strain); 
seroprotection rates - 
ƚŝƚƌĞƐA? ? ? ?ďǇǀŝƌĂůƐƚƌĂŝŶ
and by number of 
strains); seroconversion 
rates  ? 4-fold increase in 
titres (by viral strain and 
by number of strains) 
 
No significant differences between 
groups for any immune outcome at 
any time point. 
Meditation vs Control+ 
Mean fold Increase: g= .08 
Geometric Mean Titre 3 weeks: g= -.51 
Geometric Mean Titre 12 weeks: g= -.34 
Seroprotection: g= -.42 
Seroconversion: g= -.13 
 
 
Exercise vs Control+ 
Mean fold Increase: g= -.07 
Geometric Mean Titre 3 weeks: g= .23 
Geometric Mean Titre 12 weeks: g =.03 
Seroprotection: g= -.15 
Seroconversion: g= .04 
 
Meditation vs Exercise+ 
Mean fold Increase: g= .06 
Geometric Mean Titre 3 weeks: g= -.73 
Geometric Mean Titre 12 weeks:g= -.38 
Seroprotection: g= -.27 
Seroconversion: g= -.17 
 
A?ǀĞƌĂŐĞ,ĞĚŐĞƐ ?ŐĂĐƌŽƐƐǀŝƌĂůƐƚƌĂŝŶƐĂŶĚ
number of strains reported, as a total of 72 
effect sizes could be reported. Effect sizes by 
viral strains and number of strains available 
at request. 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Hsu et al. 
(1995) 
 
Taiwan 
 
Randomised 
controlled trial 
Intervention: n=175 
Control: n=152  
 
Infants recruited 
through routine 
vaccine programme 
 
2 months of age n= 
125; receiving first 
vaccine dose); 70 
male, 55 female 
 
4 months of age 
n=100; receiving 
second dose; 44 male, 
56 female 
 
6 months of age 
n=102; receiving third 
dose; 48 male, 54 
female 
Intervention: 1-minute light circular 
massage over injection site 
 
Control: no treatment 
 
Adherence: not reported, but intervention 
was a single session of supervised massage.  
 
Mediating mechanisms:  examined 
ƉĂƌĞŶƚƐ ?ƌĞƉŽƌƚƐŽĨůŽĐĂů ?Ğ ?Ő ? ?ƉĂŝŶ ?ĂŶĚ
systemic (e.g. fever) adverse reactions. 
Greater percentage of parents in 
intervention arm reported local pain and 
fever. But effects on fever not significant 
when examining fevers >39oC. 
 
Vaccination administered immediately 
prior to intervention. 
Diphtheria, tetanus, 
pertussis  
 
Diptheria: neutralisation 
assay;  
tetanus: indirect 
hemagglutinin test; 
pertussis:  
elisa measuring antibody 
to filamentous 
hemagglutinin (anti-
FHA); antibody to 
pertussis toxin (anti-PT) 
microagglutination assay 
for pertussis agglutinin 
 
2 (pre-vaccine), 6, 7, 18, 
& 19 months of age 
 
Antibody titres (log 
transformed) 
 
Compared with controls, the 
intervention group exhibited higher 
diphtheria titres at 6 and 7 months, 
but no significant between group 
differences at 18 or 19 months. At 
2 months titres were significantly 
higher in the control group. 
 
No significant between group 
differences in tetanus titres at any 
time point. 
 
Compared with controls, the 
intervention group exhibited 
significantly higher anti-FHA at 2, 6 
and 7 months; significantly higher 
anti-PT at all time points and 
significantly higher pertussis 
agglutinin titres at 18 and 19 
months, but with greater levels in 
the control group at 2 months.  
 
Insufficient details available. 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Huang & Huang 
(1999) 
 
Taiwan 
 
Randomised 
controlled trial 
Intervention:  
DTPw n=293 (of which 
107 provided a blood 
sample for antibody 
measurement);  
 
DTPa n= 107 (of which 
99 provided a blood 
sample for antibody 
measurement);  
 
Control:  
DTPw n=297 (of which 
108 provided a blood 
sample for antibody 
measurement);  
 
DTPa n= 111 (of which 
99 provided a blood 
sample for antibody 
measurement). 
 
Infants recruited 
through routine 
vaccine programme 
 
2-6 months 
 
Intervention: 2 minute massage 
immediately after vaccination and 
application of warm towel on injection site 
for 30 minutes in the evening of the 
vaccination day 
 
Control: no treatment 
 
Adherence: not reported, but first part of 
intervention was a single session of 
supervised massage. Adherence to warm 
towel application not reported. 
 
DĞĚŝĂƚŝŶŐŵĞĐŚĂŶŝƐŵƐ ?ĞǆĂŵŝŶĞĚƉĂƌĞŶƚƐ ?
reports of local (e.g., pain) and systemic 
(e.g. fever) adverse reactions. Found no 
differences between groups for DTPa but 
evidence of increased, rather than 
decreased adverse reactions (pain and 
induration) in intervention children 
receiving DTPw. 
 
Vaccination administered immediately 
prior to intervention. 
 
Diphtheria, tetanus, & 
whole-cell pertussis 
combined vaccine 
(DTPw) & diphtheria, 
tetanus and acellular 
pertussis combined 
vaccine (DTPa) 
 
Diptheria: neutralisation 
assay; tetanus: indirect 
hemagglutinin test; 
pertusus: 
microagglutination assay 
 
2 (pre-vaccine) and 7 
months of age 
 
Antibody titres (log 
transformed) 
 
No significant between group 
differences between the 
intervention group and controls in 
antibody titres of diphtheria, 
tetanus, and pertussis antibodies in 
response to the DTPw or DTPa 
vaccines. 
 
Insufficient details available. 
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ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Loft et al. (2012) 
 
New Zealand 
 
Randomised 
controlled trial 
Intervention:  n=35 
 
Control:  n=35 
 
Undergraduate 
medical students 
 
Mean age 21 years 
 
34 male, 36 female 
 
 
Intervention: 45-minute body massage 
received once a week for 4 weeks. 
 
Control: no treatment 
 
Adherence: all intervention participants 
attended all treatment sessions. 
 
Mediating mechanisms: no effect of 
intervention on measures of emotional 
distress 
 
Vaccination administered after 
intervention 
Hepatitis B (single, 
primary dose) 
 
Microparticle enzyme 
immunoassay 
 
0 (pre-vaccine), 2 & 6 
weeks post-vaccination 
 
Total serum (IgM & IgG) 
anti-HB antibody titres 
 
 
 
Compared with controls, the 
intervention group exhibited 
significantly lower anti-HB antibody 
titres at 2 weeks and 6 weeks post-
vaccination.  
At 2 weeks: g= -.68 [-1.16, -.21] 
 
At 6 weeks: g= -.40 [-.87, .07] 
Petrie et al. (1995) 
 
New Zealand 
 
Randomised 
controlled trial 
Intervention:  n=20 
 
Control:  n=20 
 
Undergraduate 
medical students 
 
Mean age 21 years 
 
21 male, 19 female 
 
Intervention: writing about traumatic 
event or events over 4 consecutive days 
 
Control: emotionally neutral writing about 
activities in recent days over 4 consecutive 
days 
 
Adherence: not reported, but degrees of 
freedom data indicate 100% adherence 
 
Mediating mechanisms: text analysis of 
written material showed intervention 
ŐƌŽƵƉ ?ƐǁƌŝƚŝŶŐǁĂƐŵŽƌĞĞŵŽƚŝŽŶĂůĂŶĚ
showed greater cognitive change 
 
Vaccination administered on the day after 
the 4th day of writing 
Hepatitis B (triple 
vaccine schedule) 
 
Microparticle enzyme 
immunoassay 
 
0 months (after 
intervention/pre-
vaccine), 1, 4, & 6 
months 
 
Anti-HB antibody titres 
(log transformed) 
 
Compared with the control group, 
the intervention group had 
increasingly higher levels of anti-HB 
antibody titres over time. 
 
This effect became non-significant 
when individuals (n=5) who were 
seropositive at baseline were 
excluded from the analyses. 
 
All participants at: 
1 month: g= .06 [-.55, .67]  
 
4 months: g= .43 [-.18, 1.05] 
 
6 months: g= .42 [-.19, 1.04] 
 
Excluding seropositive at baseline 
participants: 
1 month: g= -.21 [-.86, .44] 
 
4 months: g= .41 [-.24, 1.07] 
 
6 months: g= .37 [-.28, 1.03] 
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ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Stetler et al. (2006) 
 
Canada 
 
Randomised 
controlled trial 
Intervention:  n=26 
 
Control: n=22  
 
Healthy students 
 
Mean age 27 years 
 
Intervention group: 2 
male, 24 female 
 
Control group:  
3 male, 19 female 
 
Intervention: writing about personal 
experiences of racism for 20 minutes over 
3 days (day 1, day 1 + 5-7 days; day 2 +5-7 
days) 
 
Control: emotionally neutral writing about 
activities 20 minutes over 3 days (day 1, 
day 1 + 5-7 days; day 2 +5-7 days) 
 
Adherence: not reported, but degrees of 
freedom data indicate 100% adherence 
 
Mediating mechanisms: intervention 
participants were less positive and more 
negative after each intervention session 
 
Vaccination administered within one week 
of the 3rd day of writing 
Influenza 
 
Hemagglutination 
inhibition assay 
 
0 (pre-vaccine), 30 and 
90 days 
 
Hemagglutination 
inhibiting antibody 
slopes/change over time 
(log transformed, 
regressed on time since 
vaccination) analysed 
separately by viral strain 
(A/New Caledonia H1N1; 
A/Moscow H3N2, 
B/Sichuan) 
 
Compared with the control group, 
the intervention group had lower 
antibody slopes/change over time 
for the A/New Caledonia H1N1 and 
A/Moscow H3N2 viral strains. No 
significant between group 
differences in antibody 
slopes/change over time for the 
B/Sichuan viral strain. 
 
Post-hoc analysis of the 
intervention group only showed 
greater antibody slopes/change 
over time for the A/New Caledonia 
H1N1 strain in participants who 
attributed greater certainty their 
experiences were explained by 
racism, compared with those who 
showed expressed less certainty. 
No such relationships were 
observed for the other two viral 
strains. 
A/New Caledonia H1N1: 
30 days: g= -.14 [-.70, .42] 
 
90 days: g= -.12 [-.68, .44] 
 
A/Moscow H3N2: 
30 days: g= -.21 [-.77, .35] 
 
90 days: g= -.28 [-.85, .28] 
 
B/Sichuan: 
30 days: g= .10 [-.46, .66] 
 
90 days: g= .10 [-.45, .66] 
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ƵƚŚŽƌƐ ?ŵĂŝŶŝŵŵƵŶĞĨŝŶĚŝŶŐƐ
relating to vaccine response 
 
ĨĨĞĐƚ^ŝǌĞƐ ?,ĞĚŐĞƐ ?Ő ?ĨŽƌďĞƚǁĞĞŶ
condition differences [95% Confidence 
intervals]+ 
Vedhara et al. 
(2003) 
 
UK 
 
Matched control 
design 
Intervention: n=16 
 
Carer controls: n=27 
 
Non-carer controls: n= 
27 
 
Chronically stressed 
older adults (spousal 
carers and non-
caregiving controls) 
 
Mean age 75 years 
(carers); 71 years 
(controls) 
 
32 males, 38 females 
 
Intervention: Cognitive-behavioural stress 
management intervention; sessions 1 hour 
a week over 8 weeks 
 
Control: no treatment 
 
Adherence: all intervention participants 
attended at least 6/8 intervention sessions 
 
Mediating mechanisms: no change in 
emotional distress between groups 
 
Vaccination administered 2-3 weeks after 
final intervention session 
Influenza  
 
Enzyme-linked 
immunosorbent assay 
 
0 (pre-vaccine), 2, 4, & 6 
weeks 
 
Seroresponse: 4-fold 
increase in IgG antibody 
titres to at least one viral 
strain 
Significantly more carers in the 
intervention group were classed as 
seroresponders compared with 
carers in the control group. 
 
Seroresponder rates did not differ 
significantly between intervention 
carers and non-carer controls. 
 
Significantly more non-carer 
controls were classed as 
seroresponders compared with 
carer controls. 
Intervention vs Carer Controls: 
g= 1.13 [.41, 1.83] 
 
Intervention vs Non-carer Controls: 
g= .43 [-.19, 1.06] 
 
Carer Controls vs Non-carer controls: 
g= -.59 [-1.15, -.02] 
 
Yang et al., (2008) 
 
USA 
 
Waiting-list control 
design 
Intervention: n=27 
 
Control: n=23 
 
Older adults 
 
Intervention group: 
mean age 80 years; 6 
male, 21 female 
 
Control group: mean 
age 75 years; 7 male, 
16 female 
Intervention: combined Taiji/Qigong 
meditation; 3 x 1 hour sessions per week 
for 20 weeks 
 
Control: waiting-list control 
 
Adherence: mean attendance of 
intervention sessions 80.5% 
 
Mediating mechanisms: no relevant data 
reported. 
 
Vaccination administered during first week 
of intervention/control period 
Influenza 
 
Hemagglutination 
inhibition assay 
 
0 (pre-vaccine), 3, 6 & 20 
weeks 
 
Hemagglutination 
inhibiting antibody titres 
(composite of all viral 
strains) and 
seroprotection rates 
(titre > 40) analysed 
separately by viral strain 
 
Compared with the control group, 
intervention group had higher 
hemagglutination inhibiting 
antibody titres at 3 and 20 weeks 
post-vaccination, but not at 6 
weeks. 
 
Compared with baseline levels: 
antibody levels were significantly 
greater at 3, 6 and 20 weeks post-
vaccination in the intervention 
group; in the control group, 
antibody levels were significantly 
greater at 3 and 6 weeks only. 
 
No significant differences between 
groups in seroprotection rates for 
each viral strain. 
Insufficient details available. 
34 
MBSR= Mindfulness-based stress reduction; HI= Hemagglutination inhibiting; DTPw= Diphtheria, tetanus, & whole-cell pertussis combined vaccine; DTPa= diphtheria, tetanus and acellular pertussis combined 
vaccine; IgG= Immunoglobulin serotype G; IgM= Immunoglobulin serotype M; anti-HB= anti-hepatitis B. + Positive effect sizes should be interpreted as the trial arm listed first (typically the intervention) having 
enhanced antibody responses compared to the trial arm listed second (typically the control). Negative effect sizes indicate reduced antibody responses in the same manner 
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Figure Captions 
Figure 1:  PRISMA summary of search procedure 
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Appendix 1:  Medline search matrix as example of search strategy 
Each group of search terms were combined with the Boolean AND operator within each 
bibliographic database. 
 
Population (vaccine) 
Conjugate OR Haemophilus Vaccines OR Human OR Influenza OR Influenza vaccines 
OR Vaccin OR Vaccines OR Viral vaccines 
Intervention 
Acupressure OR Acupuncture OR Adaptation OR Affect OR Alternative medicine OR 
Alternative therapy OR Anxiety OR Autogenic training OR Behavior change OR Behaviour 
change OR Behavior modification OR Behaviour modification OR Behavior therapy OR 
Behaviour therapy OR Biofeedback OR Biofeedback training OR Breathing exercises OR 
Client education OR Cognition OR Cognitive behaviour therapy OR Cognitive behavior 
therapy OR CBT OR Cognitive performance OR Cognitive restructuring OR Cognitive therapy 
OR Cognitive techniques OR Complementary therapy OR Coping behavior OR Coping 
behaviour OR Counseling OR Counselling OR Depression OR Diet OR Education OR 
Emotional adjustment OR Emotional disclosure OR Emotional expression OR Emotions OR 
Exercise OR Exercise therapy OR Expressive writing OR Group counseling OR Group 
counselling OR Health education OR Health promotion OR Home practice OR Hypnosis OR 
Hypnotherapy OR Illness behavior OR Illness behaviour OR Interventional studies OR 
Lifestyle changes OR Massage OR Meditation OR Meditation retreat OR Mind body 
therapies OR Mind body therapy OR Mindful meditation OR Mindfulness OR Motivation OR 
Narration OR Nutrition OR Optimism OR Patient counseling OR Patient counselling OR 
Patient education OR Perceived stress OR Physical activity OR Physical education OR Physical 
37 
education training OR Physiological OR Pilates OR Preventative medicine OR Promotion 
campaign OR Psychoeducation OR Psychology OR Psychological OR Psychological 
intervention OR Psychotherapy OR Rehabilitation OR Relaxation OR Relaxation therapy OR 
Relaxation training OR Self-help groups OR Sleep OR Sleep techniques OR Social adjustment 
OR Social network OR Social care OR Social skills training OR Social support OR Stress OR 
Stress appraisal OR Stressor appraisal OR Stressors OR Stress OR Stress management OR 
Stress reduction OR Support groups OR Tai chi OR Tai ji OR Visualisation OR Yoga 
Outcome 
Antibodies OR Antibody OR Antibody formation OR Antibody maintenance OR 
Antibody-producing cells OR Antibody status OR Antibody titer OR Antigens OR Anti-
idiotypic OR Autoantibodies OR B-Lymphocytes OR Bacterial OR Cellular OR Cytokines OR 
Dendritic Cells OR Hemagglutination inhibition OR Humoral OR Humoral responses OR OR 
IgA OR IgM OR IgD OR IgE OR IgG OR Immune response OR Immune tolerance OR Immunity 
OR Immunoglobulin OR Immunologic memory OR Immunosorbent assay OR 
Immunosuppression OR Immunosuppressive agents OR Innate OR Lymphocytes OR Memory 
cells OR Primary antibody response OR Regulatory OR Secondary antibody response OR 
Seroconverted OR Seronegative OR Seropositive OR Seroprotection OR Seroprotective 
responses OR T-Lymphocytes OR Titres OR Viral 
 
